Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Subsequent Bevacizumab Treatment in Patients With HHT After the End of BABH Interventional Study. A Descriptive Study.

NCT06039124 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT06039124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06039124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Subsequent Bevacizumab Treatment in Patients With HHT After the End of BABH Interventional Study. A Descriptive Study.
Lead sponsor
Hospices Civils de Lyon
Phase
Observational
Overall status
Completed
Start date
September 1, 2021
Completion date
August 1, 2022
Enrollment
23 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hemorrhagic hereditary telangiectasia, hht